Skip to content
Fit.Archive
English
Open my log

Research update

Research Update, November 2026: Lifting Weights on Tirzepatide Cut Muscle Loss and Raised Strength in a 40-Week Trial

Photo: an older man doing a lat pulldown while a coach with a clipboard watches his form

Does lifting weights on tirzepatide (Mounjaro, Zepbound) prevent muscle loss? It reduces muscle loss rather than preventing it, and it protects strength. In a new 40-week randomised trial in Nature Medicine, 120 adults all took tirzepatide and lost about 22 kg. Those who also did supervised resistance training three times a week lost 3.57 kg of lean mass instead of 4.67 kg, and their strength rose by 10.7% to 17.5% while the non-lifting group got 6.5% to 9.0% weaker. Fat loss was the same in both groups.

This is FitArchive’s research update. For each paper we say what was tested, what it found, how much weight to give it, and what, if anything, to change. The paper is open access, so we read the full text, not only the abstract. It was published on 9 November 2026. This is not advice about any medicine: decisions about tirzepatide or any GLP-1 drug belong with your doctor.

A bathroom scale with a measuring tape, a woman doing a barbell bench press, and an older man on a leg extension machine.

What the trial measured: body composition on a scan, and strength on the bench press, lat pulldown and knee extension.

Why this trial matters

Two days ago we covered new research on GLP-1 drugs and muscle loss. In a large Lancet trial, people taking semaglutide lost 6.6% of their lean mass in 26 weeks. None of the studies in that update tested resistance training, which is the one tool you control. This trial did exactly that, with tirzepatide, the drug sold as Mounjaro and Zepbound.

A note on terms: the trial measured lean soft tissue mass with a DXA scan. That is everything except fat and bone, so it includes water and organs as well as muscle. A smaller drop in lean mass is a good sign, not a direct count of muscle kept.

The study: does lifting cut muscle loss on tirzepatide? (T-REx)

The paper. Green and colleagues, Nature Medicine, published online on 9 November 2026. Peer-reviewed, randomised controlled trial at a single centre in Australia. Eli Lilly supplied the tirzepatide and reviewed the trial protocol and a draft of the paper (for intellectual-property and safety issues; no changes were made), but provided no other funding and had no role in running the trial. Three authors, including the lead author, have received speaker fees from Lilly, and one has also advised the company. The lead author also reports support from a Western Australian state government research award.

Who took part. 120 adults, 60 men and 60 postmenopausal women, average age 57.7 (range 50 to 70). 87% had obesity and 13% overweight. They did not have diabetes or heart disease and were sedentary at the start, so these were beginners, not trained lifters.

What they did. Everyone got a weekly tirzepatide injection for 40 weeks, starting at 2.5 mg and increasing every 4 weeks toward 15 mg (most reached it). Half were randomly assigned to keep their usual activities; the other half also did resistance training:

Both groups were told to keep up protein, fibre and fluids; there was no special diet. In the people who kept food diaries, calorie and protein intake were similar in both groups. Attendance at the training sessions averaged 91%, and 93% of participants finished the trial.

What they found (40 weeks).

OutcomeTirzepatide onlyTirzepatide + lifting
Body weight−22.61 kg−22.28 kg
Fat mass−17.19 kg−17.98 kg
Lean soft tissue mass−4.67 kg−3.57 kg
Arm and leg lean mass−3.55 kg−2.92 kg
Bench press 1RM−4.09 kg (−8.4%)+4.68 kg (+10.7%)
Lat pulldown 1RM−4.42 kg (−6.5%)+8.58 kg (+15.7%)
Knee extension 1RM−4.42 kg (−9.0%)+5.88 kg (+17.5%)

How much weight to give it: high for the main question, moderate for applying it to you. It is a randomised trial with 40 weeks of follow-up, few dropouts, high attendance, DXA scans every 8 weeks and strength tested the same way in both groups. The limits:

How it fits the existing evidence

It fills the gap left by the drug trials. The Lancet COURAGE trial showed that semaglutide weight loss comes with meaningful lean-mass loss and tested an experimental antibody to reduce it. This trial shows that ordinary progressive resistance training reduced lean-mass loss on tirzepatide by about a quarter (1.09 of 4.67 kg) and, more importantly, turned a loss of strength into a gain. It also fits what is known about dieting without drugs: lifting during a calorie deficit helps keep muscle and strength, while fat loss depends mostly on the deficit itself.

What this means if you lift

If you are…Based on this trial, consider…
On tirzepatide or a similar drug and not liftingAsking your doctor about starting supervised or structured resistance training
On a GLP-1 drug and already liftingLogging your main lifts and protein so you notice early if either drops
Expecting lifting to stop all muscle lossKnowing it reduced lean-mass loss by about a quarter, not to zero
A trained lifter at a normal weightKnowing this trial did not study you; the general principles still apply

How we judge new research

This article summarises research for general education. It is not medical advice or a personal training or diet prescription. Never start, stop or change a medicine such as tirzepatide without your doctor. If you have a medical condition or are planning a large weight change, talk to a doctor first.

Track lifts, protein and your weight trend in FitArchive

FitArchive logs each set’s weight, reps and reps in reserve, and logs meals with daily calories and protein. Record one body weight reading a day to see a smoothed weight trend with the change per week, and add waist measurements in centimetres, so you can see whether strength holds while the scale moves. Try it with sample data in the demo.

All articles